TKI type switching overcomes ROS1 L2086F in ROS1 fusion-positive cancers-Reference-Cited by-同舟云学术

TKI type switching overcomes ROS1 L2086F in ROS1 fusion-positive cancers

Published:2024-08-08 Issue:1 Volume:8 Page:
ISSN:2397-768X
Container-title:npj Precision Oncology
language:en
Short-container-title:npj Precis. Onc.

Author:

Thawani Rajat^ORCID,Repetto Matteo,Keddy Clare,Nicholson Katelyn,Jones Kristen,Nusser Kevin,Beach Catherine Z.^ORCID,Harada Guilherme,Drilon Alexander^ORCID,Davare Monika A.

Funder

U.S. Department of Health & Human Services | National Institutes of Health

Oregon Early Career Investigator Award

Publisher

Springer Science and Business Media LLC

Link

https://www.nature.com/articles/s41698-024-00663-1.pdf

Reference36 articles.

1. Yu, Z.-Q. et al. ROS1-positive non-small cell lung cancer (NSCLC): biology, diagnostics, therapeutics and resistance. J. Drug Target. 30, 845–857 (2022).

2. Keddy, C. et al. Resistance profile and structural modeling of next-generation ROS1 tyrosine kinase inhibitors. Mol. Cancer Ther. 21, 336–346 (2022).

3. Davare, M. A. et al. Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors. Proc. Natl Acad. Sci. USA 112, E5381–E5390 (2015).

4. Mazieres, J. et al. Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry. Ann. Oncol. 30, 1321–1328 (2019).

5. Shaw, A. T. et al. Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001. Ann. Oncol. 30, 1121–1126 (2019).

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Author Correction: TKI type switching overcomes ROS1 L2086F in ROS1 fusion-positive cancers;npj Precision Oncology;2024-08-28

2. Advances and future directions in ROS1 fusion-positive lung cancer;The Oncologist;2024-08-23